← Eichor
Condition: Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab a
Phase 1 · 31 location(s) · Hoffmann-La Roche · NCT05091424Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compar
Phase 3 · 187 location(s) · BeOne Medicines · NCT06943872A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphom
Phase 2 · 31 location(s) · AbbVie · NCT02966756The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Phase 2 · 15 location(s) · Dizal Pharmaceuticals · NCT07154264Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Phase 1 · 9 location(s) · Ascentage Pharma Group Inc. · NCT04215809Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · 631 location(s) · National Cancer Institute (NCI) · NCT04269902Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Phase 2 · 1 location(s) · Zulfa Omer · NCT07108998DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Phase 2 · 17 location(s) · Dizal Pharmaceuticals · NCT06539182A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymp
Phase 2 · 4 location(s) · VA Office of Research and Development · NCT06520098Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Phase 1/Phase 2 · 1 location(s) · Medical University of South Carolina · NCT05702853Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphoc
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT03824483A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lympho
Phase 3 · 124 location(s) · BeOne Medicines · NCT06846671A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R
Phase 1/Phase 2 · 31 location(s) · AstraZeneca · NCT06542250Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia o
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04941716Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r
Phase 1 · 23 location(s) · Imugene Limited · NCT03666000ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Phase 3 · 4 location(s) · Newave Pharmaceutical Inc · NCT07342478Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma Wi
Phase 3 · 30 location(s) · AstraZeneca · NCT07509151Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed o
Phase 1 · 1 location(s) · University Health Network, Toronto · NCT05963217Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Phase N/A · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT07030400A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Phase 1/Phase 2 · 64 location(s) · AstraZeneca · NCT06564038Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Rel
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06859008Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · C. Babis Andreadis · NCT04545762A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocy
Phase 4 · 36 location(s) · Eli Lilly and Company · NCT06876662
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.